|Description||LDN193189 is a selective and potent ALK inhibitor with potential anticancer activity.|
|B0084-307751||50 mg||$199||In stock|
|Related CAS||1062368-62-0 (HCl); 1435934-00-1 (dihydrochloride)|
|Synonyms||4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline; LDN193189; LDN 193189; LDN-193189|
IN-1130 is a selective ALK5 inhibitor with >100 fold selectivity over p38α and a panel of 26 other serine/threonine and tyrosine kinases. It also inhibit phosph...
Belizatinib is inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Belizatinib can bind to and inhibit both ALK and TRK ki...
NVP-TAE684 is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC(50) valu...
ASP3026 is a novel and selective inhibitor for the ALK kinase. ASP3026 potently inhibited ALK kinase activity and was more selective than crizotinib in a Tyr-ki...
HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM.
TPX-0005 is an orally available and potent ATP-competitive inhibitor of ALK/ROS1/TRK (IC50= 5.3 nM for SRC, IC50= 1.01 nM, 1.26 nM and 1.08 nM for mutant ALKs i...
PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), wi...
ALK inhibitor 1
ALK inhibitor 1 is a novel and selective inhibitor for the ALK kinase.
Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2.
This active molecular is a selective inhibitor of ALK(anaplastic lymphoma kinase)which is a target found in NSCLC (metastatic non-small cell lung cancer). The I...
LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2. LDN-212854 exhibits some selectivity for ALK2 in preference to other...
Ceritinib, also known as LDK378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). In Phase I trials, LDK378 s...
CH5424802 Hcl (AF 802 Hcl; Alectinib Hcl) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.
LDN193189 is a selective and potent ALK inhibitor with potential anticancer activity.
LDN-214117 is a selective and potent ALK2 inhibitor. LDN-214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM. There are currently no effective therapi...
AP26113 is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with pote...
CEP-28122 is a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers...
ALK inhibitor 2
ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase.
K02288 is a highly selective 2-aminopyridinebased inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concentrations similar to the current le...
AZD-3463 is a potent ALK/IGF1R inhibitor with potential anticancer activity.